EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Impact of Tenofovir Alafenamide Sub‐Dermal Implant Insertion Site Scarring on Acceptability and HIV Prevention Preferences: A Prospective Cohort Study in Durban, South Africa

Tanuja N Gengiah iD, Lara Lewis, Ishana Harkoo, Nqobile Myeni, Leila E Mansoor iD, Salim S Abdool Karim, Quarraisha Abdool Karim

Journal of the International AIDS Society · 2026-04 · 29 (4)

DOI: 10.1002/jia2.70107 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the International AIDS Society, online erschienen am 16.04.2026. Verfasst von Tanuja N Gengiah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa. Hauptthemen laut MEDLINE: Adenine, Anti-HIV Agents, Cicatrix, Drug Implants. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European and Developing Countries Trial Partnership, South African National Department of Health and the South African Medical Research Council, Department of Science and Innovation and the National Research Foundation (DSI-NRF) Centre of Excellence in HIV Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The CAPRISA 018 Phase I trial evaluated the safety, tolerability and pharmacokinetics of a 110 mg tenofovir alafenamide (TAF) implant for HIV prevention in South African women. This follow‐up cohort study, CAPRISA 097, assessed the long‐term resolution of implant site reactions (ISRs) after implant removal and explored user acceptability and implant attribute preferences to inform the development of next‐generation pre‐exposure prophylaxis (PrEP) implants.

Methods

Women previously enrolled in CAPRISA 018 were recruited and followed quarterly for 12 months between 13 October 2022 and 27 October 2023. ISR prevalence, severity and resolution were evaluated at each visit. Implant acceptability, implant attribute preferences and PrEP preferences were assessed at enrolment and at month 12.

Results

Of 36 eligible participants, 35 were enrolled a median of 299 days after implant removal (IQR: 243–490). At enrolment, all 35 participants (100%) had ongoing mild (Grade 1) scarring, with additional findings of hyperpigmentation (14%), induration (6%) and hypopigmentation (3%). By study exit, scarring persisted in all participants (median duration: 623 days; IQR: 579–819), while hyperpigmentation and induration remained in two and one participant, respectively. Acceptability ratings for implant visibility were similar at enrolment and month 12 (77.1% vs. 75.0%), as were ratings for pain (68.6% vs. 78.1%). Side effects due to ISRs received the highest “very unacceptable” ratings, in 37.1% of participants at enrolment and 21.9% at study exit. Scarring was considered acceptable by 65.7% of participants at enrolment, increasing to 78.1% at exit. Perceived partner interest in the various PrEP products aligned with participant interest. A palpable 12‐month implant was acceptable to most participants, whereas increased length, width or stiffness reduced the likelihood of use. Preferred PrEP options were a 12‐monthly implant (38.2% at enrolment vs. 50.0% at month 12), a 6‐monthly injection (29.0% vs. 37.5%) and daily oral PrEP tablets (12.0% vs. 3.0%).

Conclusions

Mild but persistent scarring was observed following TAF implant removal, with limited cases of hyperpigmentation and induration. Despite these local side effects, a 12‐monthly implant remained the most preferred PrEP option among women previously enrolled in the TAF implant trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineAnti-HIV AgentsCicatrixDrug ImplantsHIV InfectionsPatient Acceptance of Health CarePre-Exposure ProphylaxisTenofovirAdultFemaleHumansMiddle AgedYoung AdultAlanineFollow-Up StudiesProspective StudiesSouth Africa

Stichwörter der Autor:innen

PrEP preferencesTAFacceptabilityimplantimplant site reactionsscarring

Substanzen

AdenineAlanineAnti-HIV AgentsDrug ImplantsTenofovirtenofovir alafenamide

Autor:innen und Institutionen

  • Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
  • Department of Epidemiology, Columbia University Mailman School of Public Health, New York City, New York, USA.

ORCID-Profile: Tanuja N Gengiah, Leila E Mansoor

Förderung

  • European and Developing Countries Trial Partnership
  • South African National Department of Health and the South African Medical Research Council
  • Department of Science and Innovation and the National Research Foundation (DSI-NRF) Centre of Excellence in HIV Prevention

Zitieren

APA

Gengiah, T. N., Lewis, L., Harkoo, I., Myeni, N., Mansoor, L. E., Karim, S. S. A., & Karim, Q. A. (2026). Impact of Tenofovir Alafenamide Sub‐Dermal Implant Insertion Site Scarring on Acceptability and HIV Prevention Preferences: A Prospective Cohort Study in Durban, South Africa. Journal of the International AIDS Society, 29(4). https://doi.org/10.1002/jia2.70107

Vancouver

Gengiah TN, Lewis L, Harkoo I, Myeni N, Mansoor LE, Karim SSA, et al. Impact of Tenofovir Alafenamide Sub‐Dermal Implant Insertion Site Scarring on Acceptability and HIV Prevention Preferences: A Prospective Cohort Study in Durban, South Africa. Journal of the International AIDS Society. 2026;29(4). doi:10.1002/jia2.70107

BibTeX
@article{Gengiah2026,
  author = {Gengiah, Tanuja N and Lewis, Lara and Harkoo, Ishana and Myeni, Nqobile and Mansoor, Leila E and Karim, Salim S Abdool and Karim, Quarraisha Abdool},
  title = {Impact of Tenofovir Alafenamide Sub‐Dermal Implant Insertion Site Scarring on Acceptability and HIV Prevention Preferences: A Prospective Cohort Study in Durban, South Africa},
  journal = {Journal of the International AIDS Society},
  year = {2026},
  volume = {29},
  number = {4},
  doi = {10.1002/jia2.70107}
}
Kostenlos starten →